Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Encorafenib, sold under the brand name Braftovi, is an anti-cancer medication used for the treatment of certain melanoma cancers. It is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway. This pathway occurs in many different cancers including melanoma and colorectal cancers.
Read the full article on WikipediaUnresectable Stage III or Stage IV malignant melanoma Clinical criteria: Treatment Phase: Initial treatment The condition must be positive for a BRAF V600 mutation, AND The condition must not have been treated previously with PBS-subsidised BRAF inhibitor therapy for unresectable Stage III or Stage IV disease; OR Patient must have developed intolerance to other BRAF inhibitors of a severity necessitating permanent treatment withdrawal, AND Patient must not have experienced disease progression whilst on adjuvant BRAF inhibitor treatment or disease recurrence within 6 months of completion of adjuvant BRAF inhibitor with MEK inhibitor treatment if previously treated for resected Stage IIIB, IIIC or IIID melanoma, AND Patient must have a WHO performance status of 2 or less.
Metastatic colorectal cancer Clinical criteria: Treatment Phase: Initial treatment Patient must have BRAF V600 variant positive metastatic colorectal cancer, AND The treatment must be in combination with cetuximab, AND Patient must not have received prior treatment with cetuximab for this condition; OR Patient must not have developed disease progression while receiving cetuximab for this condition, AND Patient must not have previously received PBS-subsidised treatment with this drug for this condition, AND The condition must have failed to respond to at least one other line of systemic therapy, AND Patient must have a WHO performance status of 2 or less.
Working under the parallel aged-care framework? Aged-care equivalent →